Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection(Anti-PD-1/CTLA-4 Bispecific Antibody) Combined With Recombinant Human GM-CSF Oncolytic HSV-2 (OH2) Injection (Vero Cells) for Perioperative Treatment of Stage III Resectable Acral Melanoma: A Prospective, Randomized, Controlled, Multicenter Clinical Study

NCT07854522 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07854522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07854522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection(Anti-PD-1/CTLA-4 Bispecific Antibody) Combined With Recombinant Human GM-CSF Oncolytic HSV-2 (OH2) Injection (Vero Cells) for Perioperative Treatment of Stage III Resectable Acral Melanoma: A Prospective, Randomized, Controlled, Multicenter Clinical Study
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2030
Enrollment
76 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acral melanoma, melanoma